此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Efficacy of Acupuncture in the Treatment of Fibromyalgia

Fibromyalgia (FM), one of the most common rheumatic conditions, is a condition of unknown etiology characterized by widespread muscle pain and stiffness. Treatment is generally unsatisfactory and most randomized, controlled treatment trials have been unable to demonstrate a sustained effective intervention. A single, brief trial of electroacupuncture demonstrated remarkable improvement among patients with FM, although lasting effects were not evaluated. Nonetheless, the recently published National Institutes of Health Consensus Development Statement on Acupuncture says "musculoskeletal conditions such as fibromyalgia, myofascial pain ....are conditions for which acupuncture may be beneficial". Thus, 96 patients will be recruited from a referral clinic for fatigue for a 12 week (24 treatments) trial. These patients will be randomized into 3 control groups and 1 "true" acupuncture group. The control groups will consist of a group receiving acupuncture treatment for an unrelated condition (morning sickness), a group receiving needle insertion at non-channel, non-point locations, and a "true" placebo group. This latter group will have acupuncture needle guides tapped on the skin, then needles tapped. Thus, the specific aims of this study are to 1) evaluate the short and long term efficacy and side effects of a 12 week randomized, controlled trial of bi-weekly acupuncture in the treatment of FM; 2) establish the most useful and scientifically sound control group for studies of acupuncture using FM as a model for conditions characterized by chronic pain; 3) use both subjective and objective measures of overall health and pain to determine the optimal time length of treatment; and 4) examine the concordance of allopathic and acupuncture-based measures of outcome. For the purposes of this study, subjects will be asked to complete a unique set of study measures at enrollment, at 4, 8, and 12 weeks, and then again at 1 and 6 months post-treatment. Our primary outcomes will be patient global assessment, subjective pain, and mean number of tender points. Secondary outcomes will be pain threshold, analgesic use, physician global assessment, functional status, sleep, psychological distress, and fatigue. Thus, this trial will have both immediate and longer term implications for the scientific study of acupuncture as well as the clinical care of the estimated 5 million patients with FM in the US. From a methodological point of view, the proposed trial will establish the most appropriate methods for choosing a control group should larger trials be conducted, suggest the optimum duration of treatment, and evaluate the utility of diverse allopathic and alternative outcome measures. Of equal importance, however, this research will test and potentially establish the effectiveness of acupuncture.

研究概览

地位

完全的

条件

干预/治疗

详细说明

See brief summary

研究类型

介入性

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Washington
      • Seattle、Washington、美国、98104
        • Harborview Medical Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Non-pregnant, non-nursing
  • Have FM as diagnosed according to the 1990 ACR guidelines at some time but not necessarily currently
  • Have a global pain score of >4 on a visual analog scale (VAS, 1=no pain, 10=worst pain)
  • Not have another concurrent medical condition associated with significant diffuse neuropathic, musculoskeletal, or joint pain such as diabetic neuropathy, systemic lupus erythematosus, rheumatoid arthritis or severe multi-joint degenerative joint disease
  • Not have a history of, or any clinical indication of, a bleeding diathesis
  • Not be using narcotics on daily, regular basis
  • Not have previously received acupuncture (i.e., be acupuncture naive)
  • Not be concurrently participating in any other clinical trials
  • Try to stay on a stable medical regiment during the entire course of treatment
  • Willing to undergo randomization
  • Live within one hour of a treatment site and able to come on a regular basis for treatments
  • Not have a pacemaker
  • Be able to give consent

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Debra S. Buchwald, MD、Harborview Injury Prevention and Research Center

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2000年9月1日

研究完成

2002年7月1日

研究注册日期

首次提交

2001年2月2日

首先提交符合 QC 标准的

2001年2月2日

首次发布 (估计)

2001年2月5日

研究记录更新

最后更新发布 (估计)

2008年3月7日

上次提交的符合 QC 标准的更新

2008年3月5日

最后验证

2008年3月1日

更多信息

与本研究相关的术语

其他研究编号

  • R01AT000003-01 (美国 NIH 拨款/合同)

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅